Lysophosphatidic acid (LPA) is a lysophospholipid produced by activated platelets that inhibits adenylate cyclase and stimulates DNA synthesis, changes in cell morphology, and increases in intracellular calcium in a variety of cultured mammalian cells. A growing family of GPCRs mediates the biological effects of LPA. The first LPA receptors described, LPA1-3, share relatively high sequence similarity and are related to the sphingosine 1-phosphate receptors S1P1-6. Two more recently characterized LPA receptors, LPA4 and LPA6, are related to each other but are more distantly related to LPA1-3. LPA6, originally known as GPR92, mediates LPA-induced cytoskeletal changes, intracellular calcium flux and increased cAMP by coupling to G12/13, Gq, and Gs. In addition to binding LPA, LPA6 is also activated by several other lipid-derived molecules, the most potent of which is farnesyl pyrophosphate. GPR92 is expressed in several tissues, most prominently in the CD8+ intraepithelial lymphocytes of the gastrointestinal tract.
|Product Type||GPCR Expressing Cell|
|Catalog||Product Name||Gene Name||Species||Morphology||Price|
|ACC-RG0288||Mouse Lpar5-FLAG Stable Cell Line-RH7777||Lpar5||Mouse||Epithelial||INQUIRY|
|ACC-RG0287||Human LPAR5-FLAG Stable Cell Line-RH7777||LPAR5||Human||Epithelial||INQUIRY|
|ACC-RG1514||Human LPAR5/beta-Arrestin Stable Cell Line-CHO||LPAR5||Human||Epithelial-like||INQUIRY|